SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-doping control
- 715 Downloads
HPLC is considered the method of choice for the separation of various classes of drugs. However, some analytes are still challenging as HPLC shows limited resolution capabilities for highly polar analytes as they interact insufficiently on conventional reversed-phase (RP) columns. Especially in combination with mass spectrometric detection, limitations apply for alterations of stationary phases. Some highly polar sympathomimetic drugs and their metabolites showed almost no retention on different RP columns. Their retention remains poor even on phenylhexyl phases that show different selectivity due to π–π interactions. Supercritical fluid chromatography (SFC) as an orthogonal separation technique to HPLC may help to overcome these issues. Selected polar drugs and metabolites were analyzed utilizing SFC separation. All compounds showed sharp peaks and good retention even for the very polar analytes, such as sulfoconjugates. Retention times and elution orders in SFC are different to both RP and HILIC separations as a result of the orthogonality. Short cycle times could be realized. As temperature and pressure strongly influence the polarity of supercritical fluids, precise regulation of temperature and backpressure is required for the stability of the retention times. As CO2 is the main constituent of the mobile phase in SFC, solvent consumption and solvent waste are considerably reduced.
KeywordsSympathomimetic drugs Beta-blockers Polar stimulants Doping control Sulfoconjugates Dilute-and-inject
The World Anti-Doping Agency is acknowledged for their financial support (research grant 14A03KP). The authors thank Mr. Felix Bredendiek for technical assistance.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 10.Grand-Guillaume Perrenoud A, Veuthey JL, Guillarme D. Comparison of ultra-high performance supercritical fluid chromatography and ultra-high performance liquid chromatography for the analysis of pharmaceutical compounds. J Chromatogr A. 2012;1266:158–67. doi: 10.1016/j.chroma.2012.10.005.CrossRefGoogle Scholar
- 12.Bartle KD. Theory and principles of supercritical fluid chromatography. In: Smith RM, editor. Supercritical fluid chromatography. Loughborough: Royal Society of Chemistry; 1988. p. 1–28.Google Scholar
- 13.Langley GJ. Supercritical fluid chromatography (SFC). 2012. http://www.southampton.ac.uk/~gjl/Research/sfc.htm. Accessed 20 Jan 2014.
- 14.King JW, Hill HH, Lee ML. Analytical supercritical fluid chormatography and extraction. In: Rossiter BW, Baetzold RC, editors. Physical methods of chemistry series, vol X. 2nd ed. Hoboken: Wiley; 1993.Google Scholar
- 16.Parr MK, Bokland MH, Liebetrau F, Schmidt AH, Schänzer W, Sterk SS. Enantiomeric separation of clenbuterol as analytical strategy to distinguish abuse from meat contamination. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, editors. Recent advances in doping analysis (21). Cologne: Sportverlag Strauß; 2013. p. 26.Google Scholar
- 17.Doue M, Dervilly-Pinel G, Pouponneau K, Monteau F, Le Bizec B. Analysis of glucuronide and sulfate steroids in urine by ultra-high-performance supercritical-fluid chromatography hyphenated tandem mass spectrometry. Anal Bioanal Chem. 2015;407(15):4473–84. doi: 10.1007/s00216-015-8573-x.CrossRefGoogle Scholar
- 18.Novakova L, Grand-Guillaume Perrenoud A, Nicoli R, Saugy M, Veuthey JL, Guillarme D. Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. I: Investigation of mobile phase and MS conditions. Anal Chim Acta. 2015;853:637–46. doi: 10.1016/j.aca.2014.10.004.CrossRefGoogle Scholar
- 20.Novakova L, Rentsch M, Grand-Guillaume Perrenoud A, Nicoli R, Saugy M, Veuthey JL, et al. Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. II: analysis of biological samples. Anal Chim Acta. 2015;853:647–59. doi: 10.1016/j.aca.2014.10.007.CrossRefGoogle Scholar
- 21.Görgens C, Guddat S, Orlovius AK, Sigmund G, Thomas A, Thevis M, et al. “Dilute-and-inject” multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing. Anal Bioanal Chem. 2015;407(18):5365–79. doi: 10.1007/s00216-015-8699-x.CrossRefGoogle Scholar
- 23.Parr MK, Orlovius A, Guddat S, Gütschow M, Thevis M, Schänzer W. Sulfoconjugates of heavy volatile nitrogen containing doping substances for improved LC-MS/MS screening. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, editors. Recent advances in doping analysis (15). Köln: Sport und Buch Strauß; 2007. p. 97–102.Google Scholar
- 25.Orlovius A, Guddat S, Parr M, Koch A, Gütschow M, Thevis M, et al. Identification and monitoring of octopamine sulfoconjugate in urine by LC/(ESI)-MS/MS. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, editors. Recent advances in doping analysis (19). Cologne: Sportverlag Strauß; 2011. p. 34–43.Google Scholar
- 26.Mazzarino M, de la Torre X, Botre F. A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Anal Bioanal Chem. 2008;392(4):681–98. doi: 10.1007/s00216-008-2292-5.CrossRefGoogle Scholar
- 27.World Anti-Doping Agency. Mimimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes - TD2015IDCR. World Anti-Doping Agency. 2015. https://www.wada-ama.org/en/resources/science-medicine/td2015-idcr. Accessed 11 Oct 2015.
- 28.World Anti-Doping Agency. Mimimum required performance levels for detection and identification of non-threshold substances - TD2015MRPL. World Anti-Doping Agency. 2015. https://www.wada-ama.org/en/resources/science-medicine/td2015-mrpl. Accessed 11 Oct 2015.